EGFR and non-small cell lung carcinoma: Thus, compounds 1 (gefitinib) and 2 (erlotinib), two of the first-generation EGFR-targeted small molecule inhibitors (Fig. 1) have been used in clinic for the treatment of advanced NSCLC patients harboring these specific activating mutations.